Neuren Pharmaceuticals Partner Projects $700M Global Sales for Rett Syndrome Drug by 2028 as Australian Shares Stay Flat
Neuren Pharmaceuticals Forecasts Major Growth in Rett Syndrome Drug Neuren Pharmaceuticals Ltd, listed on the ASX as NEU, has projected global sales of up to US$700 million for its Rett syndrome treatment, trofinetide, by 2028. The announcement reflects confidence in the drug’s commercial potential following recent clinical and regulatory milestones in the United States and…